<DOC>
	<DOCNO>NCT00243685</DOCNO>
	<brief_summary>DiaTech private company perform patient specific cancer chemosensitivity test patient physician . DiaTech Oncology clinical study see experimental new technology call microculture kinetic ( MiCK ) assay predict treatment outcome help direct chemotherapy cancer subject . This study focus subject diagnose breast , ovarian , lung , colon malignancy low-grade lymphoma . Study Objectives : - To evaluate ability MiCK assay predict outcome chemotherapy cancer patient . - To evaluate ability MiCK assay guide chemotherapy cancer patient .</brief_summary>
	<brief_title>Chemotherapy Drug Sensitivity Microculture ( MiCK ) Assay Apoptosis</brief_title>
	<detailed_description>Application Microculture Kinetic ( MiCK ) Assay Apoptosis Testing Drug Sensitivity Solid Tumors DiaTech Oncology , LLC -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- - 1.0 Background Rationale : Despite use aggressive treatment protocol , le 10 % cancer patient advance disease respond therapy . There variety different cancer drug regimen , approximately probability clinical effectiveness . Identification patient respond specific chemotherapy important making decision regard chemotherapy regimen well alternative management approach . A laboratory test could help determine sensitivity individual patient 's tumor cell specific chemotherapeutic agent would valuable choose optimal chemotherapy regimen patient expectation increase response rate therapy . Several type vitro assay measure tumor cell survival follow exposure cytotoxic agent evaluate ability predict chemotherapy outcomes . As group , assays refer drug resistance assay . In resistance assay , survive tumor cell detect directly exclusion metabolism specific dye . Alternatively , since tumor cell proliferate , survival detect measurement DNA synthesis radiolabeled precursor incorporation demonstration clonogenic potential growth colony semi-solid culture medium . In several clinical study , assay useful detect drug resistance predict poor prognosis cancer patient . However , resistance assay detect sensitivity individual patient 's tumor cell specific drug . Therefore , new method determine drug-sensitivity tumor cell individual patient , thus , capable predict positive treatment outcome guide chemotherapy , would significant value . Recently , Dr. Kravtsov develop automated microculture kinetic ( MiCK ) assay measure drug induce apoptosis tumor cells1-4 . Apoptosis distinct mode cell death occur physiological condition yet induce malignant cell chemical physical factor include antitumor drugs5-7 . During last decade , recognize chemotherapeutic agent exert antitumor activity trigger apoptosis susceptible tumor cells8-17 . This imply MiCK assay apoptosis provide mechanism-based approach study effect cytotoxic agent tumor cell . Unlike `` resistance '' assay measure fraction cell survive drug exposure , MiCK assay measure fraction tumor cell kill chemotherapeutic agent via mechanism apoptosis . Therefore MiCK assay determines drug sensitivity , rather resistance . Recently MiCK assay show predict complete remission rate survival acute myeloid leukemia patient well clinical criterion did18-20 . In limited study , MiCK assay use direct chemotherapy leukemia patient 21 . The MiCK assay also use study drug-induced apoptosis solid tumor , include neuroblastoma colon adenocarcinoma cell lines22-23 . More recent data accumulate DiaTech demonstrate MiCK assay detect drug induce apoptosis primary culture tumor cell isolated patient ovarian carcinoma , gastric carcinoma , metastatic breast cancer high grade soft tissue sarcoma . Based data , suggest MiCK assay may use detect drug sensitivity profile individual patient various type solid tumor . This , turn , may provide way tailor chemotherapy individual patient 's drug sensitivity profile , , thus , improve treatment outcome , decrease adverse effect chemotherapy , increase quality patient 's life , reduce treatment cost . 2.0 Study Objectives : 2.1 To evaluate ability MiCK assay predict outcome chemotherapy cancer patient . 2.2 To evaluate ability MiCK assay guide chemotherapy cancer patient . 3.0 Patient Population : 3.1 Inclusion criterion : 3.1.1 Patients pathological diagnosis breast , lung , ovarian adenocarcinoma soft tissue sarcoma . 3.1.2 Patients de novo malignancy previous chemotherapy 3.1.3 Patients advanced refractory malignancy receive 2 standard chemotherapy treatment protocol . 3.1.4 Patients age group . 3.1.5 Patients must tumor accessible agree undergo biopsy , drainage effusion . 3.1.6 Patients chemotherapy treatment option . 3.2 Explanations : We anticipate newly diagnose patient mostly used evaluate ability MiCK assay predict outcome chemotherapy ( Objective # 2.1 ) establish criterion correlate numerical response MiCK assay probability clinically establish complete remission . The patient refractory malignancy mostly use evaluate ability MiCK assay guide cancer chemotherapy ( Objective # 2.2 ) . Patients see manage outpatient inpatient , depend clinical standard institution . 3.3 Exclusion criterion : 3.3.1 Patients symptomatic/uncontrolled parenchymal brain metastasis accessible tumor . 3.3.2 Patients meningeal metastasis . 3.3.3 Patients chemotherapy clinically indicate . 3.3.4 Pregnancy . During course study , patient childbearing potential instruct contact treat physician suspect might conceive child ; female , miss late menstrual period report treating physician . If pregnancy confirm pregnancy test , patient must receive study medication must enrol study , already enrol , must withdraw study . If male patient suspect father child study drug , pregnant female partner must notify counsel regard risk fetus . Pregnancy course study report Principal Investigator serious adverse event . Women child bear potential define include female experienced menarche undergone successful surgical sterilization ( hysterectomy , bilateral tubal ligation , bilateral oophorectomy ) post-menopausal ( define amenorrhea 12 consecutive month ) ; include also female use oral , implanted , injectable contraceptive hormone , mechanical device , barrier method prevent pregnancy . 4.0 Treatment Plan : 4.1 For patient involve Study Objective ( 2.1 ) , treatment protocol individual influence result MiCK assay patient . Oncologists blind result MiCK assay patient treat accord standard treatment protocol . When available , actual clinical response treatment compare predict MiCK assay . 4.2 For patient involve Study Objective ( 2.2 ) , treatment protocol individual patient design base result MiCK assay patient . The drug best activity assay use treat individual patient . If one drug equally active , patient receive active drug class he/she receive . If drug find activity ( insensitivity assay ) , patient treat empiric basis class drug he/she never receive past . 5.0 Definition Clinical Response 5.1 All patient evaluate clinical response chemotherapy per standard protocol establish specific malignancy . 5.1.1 Complete Remission define total disappearance clinically radio logically detectable disease least four week . 5.1.2 Partial Response define least 50 % reduction measurable tumor lesion measure sum product perpendicular diameter great dimension measurable lesion , new lesion appear least four week . 5.1.3 Stable Disease define reduction le 50 % increase le 25 % size tumor lesion , new lesion appear . 5.1.4 Progressive Disease define appearance new tumor lesion increase 25 % sum product perpendicular diameter great dimension measurable exist lesion . 6.0 Definition drug response MiCK assay . 6.1 In MiCK assay , extent drug-induced apoptosis measure Kinetic Units ( KU ) scale 0 16 ( Blood , 1998 ) . Apoptotic response KU calculate dose test drug drug combination . The maximal numerical response induce drug consider `` best apoptotic response '' drug . 6.1.1 Under Study Objective ( 2.1 ) , `` best apoptotic response '' drug compare clinical response drug establish numerical value vitro response discriminate drug-sensitive drug-insensitive tumor ( establish numerical cut-off sensitivity ) . From experience establish cut-off value drug sensitivity acute leukemia , 25-30 patient provide sufficient statistical power get significant discriminator . These 25-30 patient fed patient participate Study Objective ( 2.1 ) Study Objective ( 2.2 ) . After numerical cut-off sensitivity establish , apply cohort patient receive treatment drug compare response predict MiCK assay actual clinical response . This second part study two leg : ( ) `` prospective '' ( use 30-35 patient enter study establish discriminator , ( b ) `` retrospective '' ( use available database patient receive treatment past 's clinical response chemotherapy know ) . 6.1.2 For patient participate Study Objective ( 2.2 ) , drug inducing high `` best apoptotic response '' consider best active drug recommend include treatment protocol . Only drug numerical value `` best apoptotic response '' exceed certain threshold expect induce complete remission . In begin study , threshold judge base result previous leukemia study19-22 . As first 25-30 patient enter study , threshold establish solid tumor patient describe ( 6.1.1 ) use thereafter . Considering 25-30 patient fed patient participate Study Objective ( 2.1 ) Study Objective ( 2.2 ) , expect first statistical correlation available later 3-4 month study begin . 6.1.3 Drug selection test tumor cell base previous chemotherapy history individual patient consideration future treatment plan . The drug select compendium agent recommend treatment patient 's malignancy . 7.0 Statistics 7.1 We estimate sufficient statistical power obtain approximately 50-60 patient successful MiCK assay . A successful MiCK assay define assay sufficient number viable tumor cell could isolate submit pathologic material . For correlation patient 's sensitivity profiling MiCK assay clinical response , patient evaluate whole group well stratify base type malignancy . The latter depend number patient specific tumor type available study . 7.2 In order discriminate drug-sensitive drug insensitive tumor cell population , best response agent compare receiver operator characteristic ( ROC ) analysis well logistic regression analysis attainment CR ( CR vs No CR ) . Based best combination statistical sensitivity , specificity , p value , threshold demarcate drug sensitivity insensitivity establish . The Fisher 's exact test , chi-square test analysis variance method employ test correlation clinical response result clinical variable . For lifetime data analysis , Kaplan-Meier estimate survival use . Other statistical technique may also imply find useful . 8.0 Specimen collection , purification tumor cell sensitivity test 8.1 Specimen collection must perform per relate DiaTech Standard Operating Procedures ( SOP ) . 8.1.1 Collection Solid Tumor Biopsy Specimen perform sterile condition , use excision biopsy technique , obtain least 2 cm3 viable tumor tissue . The viable tumor tissue submit study , chemotherapeutic agent test tumor cell . Effusion specimen ( peritoneal fluid , pleural fluid effusion anatomical site ) collect commercial sterile container/bag add Sodium Heparin ( 10 U/ml ) prevent clot . The sample size le 500 ml . The specimen fix , frozen . 8.1.2 Transportation : seal transport tube/container/bag tightly . Label specimen institution , patient name , date time collection , anatomical site collection . Place transport tube/container/bag ice pack ( blue ice ) . Ice pack must freeze place container . Fill Study Requisition form include transportation container . 8.1.3 Place 50 mL tube container inside zip-lock bag seal . Place specimen Cold Pak ( blue ice ) transport box . Place complete patient information form specimen transport box FedEx plastic `` Diagnostic Specimen Envelope '' seal . Complete affix FedEx Airbill outside Diagnostic Specimen Envelope . Be sure airbill mark `` FedEx Priority Overnight '' delivery . Put $ 5 value FedEx Airbill . Indicate `` Human tissue diagnostic study '' appropriate section FedEx Airbill . Call DiaTech Oncology ( 514 ) -398-5174 ( Steve Moisan , lab manager ) ( 514 ) -398-5154 ( general lab ) Fed Ex Tracking Number . DiaTech must receive specimen within 24 hour collection . Specimens send Friday must mark Saturday delivery . 8.2 Tumor cell purification chemosensitivity test perform per relate DiaTech SOPs . 8.2.1 Tissue biopsy effusion specimen treat obtain suspension contain single tumor cell and/or small cell aggregate compose 2-20 tumor cell . Using gradient centrifugation , red blood cell lysing , cell strainer , magnetic bead appropriate technique , tumor cell suspension enrich least 80 % purity le 90 % viability . Immunocytochemical stain , applicable , flow cytometry use confirm presence specific tumor marker purify cell After purification , select chemotherapeutic agent test purified tumor cell MiCK assay . 8.2.2 The purified tumor cell suspended culture medium plat 96-well microtiter plate . Multiple concentration chemotherapeutic agent achieve add respective agent well 5 Î¼L aliquot The range final drug concentration base report pharmacokinetic study drug active metabolite patient . Data processing quantification drug-induced apoptosis perform proprietary ProApoTestTM software . The extent apoptosis determine express kinetic unit ( KU ) apoptosis . 9.0 Efficacy measurement 9.1 For patient participate Study Objective ( 2.1 ) , goal study establish statistically significant discriminator sensitivity would correlate rate CR . Such discriminator applicable patient 's population participate Study Objectives ( 2.1 ) ( 2.2 ) . 9.2 For patient participate Study Objective ( 2.2 ) , would expect great 10 % response rate refractory solid tumor patient standard chemotherapy . A response rate MiCK assay-guided therapy le 10 % would interest . A response rate 10-30 % suggest MICK assay need study . A response rate great 30 % would justify usefulness MiCK assay guide chemotherapy patient refractory solid tumor . 10.0 Specimen 's leave 10.1 If specimen contain tumor cell need test sensitivity drug specify patient 's oncologist , excess tumor cell may consider use research study conduct DiaTech Oncology . Patients ask permission use specimen 's leave research purpose sign follow release include requisition form : `` You participate Research Program may result improvement treatment outcome cancer patient . There direct benefit present time . Your physician submitting DiaTech specimen contain tumor cell . At DiaTech , purify tumor cell , count , check viability , store DiaTech Tissue Bank . All procedure perform cost family . Your cell may use chemosensitivity test research purpose study . Results research may publish , use commercially area new anti-cancer drug treatment protocol development . To assure privacy , result study publish , refer number . Your signature indicate agree term '' . If patient refuse sign release , specimen 's left decontaminate use 10 % formaldehyde 24h discard per relate SOP . If patient grant his/her permission use specimen 's left future research , excess tumor cell frozen store liquid nitrogen indefinitely . 10.2 Specimen 's left may use study anti-tumor effect chemotherapeutic drug drug combination , study mechanism drug resistance , correlate phenotypic feature tumor cell drug sensitivity profile . 11.0 Plan communication Principal Investigator co-Principal Investigator . To insure proper communication Vladimir Kravtsov , MD , Study Principal Investigator , participate co-Principal Investigator follow communication mean use : FedEx delivery print material , Phone &amp; Fax , E-mail , Video-conferencing 11.1 At time submission patient 's specimen study , relevant clinical information submit DiaTech form study requisition form prepare participate co-PI ( designated staff nurse ) use FedEx courier service . 11.2 Upon receive specimen requisition form purification tumor cell specimen , Dr. Kravtsov place telephone call refer oncologist ( co-PI ) discus case . 11.3 Upon completion patient 's tumor drug sensitivity testing , result score introduced study data base . Dr. Kravtsov issue study report fax refer oncologist later 96h receive specimen . After fax report , Dr. Kravtsov call refer oncologist discuss result . 11.4 After 2 cycle therapy , patient 's treatment response evaluate refer oncologist ( co-PI ) . A study Response Evaluation Form ( see attach ) fill faxed DiaTech include study data base . 11.5 After data first ten consecutive patient collect , telephone video conference schedule Dr. Kravtsov co-PI summarize discus preliminary result . 11.6 After data first 30 consecutive patient collect , interim statistical analysis perform Dr. Kravtsov visit participate hospital present discus result co-Principal investigator . 11.7 At end first year , statistical analysis accumulate data perform participate co-PIs invite conference ( place determine ) discus result . 11.8 DiaTech Study coordinator ( Mr. Garry Latimer ) contact site co-PI designated nurse monthly assure proper supply transportation container address administrative issue . 11.9 All communication study coordinator participate oncology practice document , report Principal Investigator , discuss co-Principal Investigator . APPENDIX A TREATMENT PLAN ALGORITHM FOR STUDY OBJECTIVE 2.1 Study Objective 2.1 : To evaluate ability MiCK assay predict outcome chemotherapy patient solid tumor first- second-line treatment . Chemotherapeutic agent ( ) include treatment protocol select medical oncologist base publish standard treatment guideline . Chemotherapy patient initiate per clinical treatment protocol oncologist discretion . Name ( ) drug ( ) select treatment provide DiaTech lab along tumor material obtain patient . Tumor cell purify patient 's specimen test sensitivity drug select patient 's treatment . Results drug sensitivity test score introduce study database . After cycle therapy , patient evaluate response treatment per establish criterion ( clinical exam , CT , tumor marker ) . Actual treatment response drug compare drug score vitro drug sensitivity test . APPENDIX B TREATMENT PLAN ALGORITHM FOR STUDY OBJECTIVE 2.2 Study objective 2.2 : To evaluate ability MiCK assay guide chemotherapy cancer patient third line , refractory treatment set . Chemotherapeutic agent available treatment identify medical oncologist base publish standard treatment guideline . Names drug provide DiaTech lab along tumor material obtain patient . Tumor cell purify patient 's specimen test sensitivity drug select patient 's oncologist . Results drug sensitivity test score , introduce study database , report medical oncologist . The drug best anti-tumor activity assay use treat patient . After cycle therapy , patient evaluate response treatment per establish criterion ( clinical exam , CT , tumor marker ) .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<criteria>Patients pathological diagnosis breast , lung , ovarian adenocarcinoma soft tissue sarcoma . Patients de novo malignancy previous chemotherapy Patients advance refractory malignancy receive 2 standard chemotherapy treatment protocol . Patients age group . Patients must tumor accessible agree undergo biopsy , drainage effusion . Patients chemotherapy treatment option . Patients symptomatic/uncontrolled parenchymal brain metastasis nonaccessible tumor . Patients meningeal metastasis . Patients chemotherapy clinically indicate . Pregnancy . During course study , patient childbearing potential instruct contact treat physician suspect might conceive child ; female , miss late menstrual period report treating physician . If pregnancy confirm pregnancy test , patient must receive study medication must enrol study , already enrol , must withdraw study . If male patient suspect father child study drug , pregnant female partner must notify counsel regard risk fetus . Pregnancy course study report Principal Investigator serious adverse event . Women childbearing potential define include female experienced menarche undergone successful surgical sterilization ( hysterectomy , bilateral tubal ligation , bilateral oophorectomy ) postmenopausal ( define amenorrhea 12 consecutive month ) ; also include female use oral , implanted , injectable contraceptive hormone , mechanical device , barrier method prevent pregnancy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Chemosensitivity</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Lung cancer</keyword>
	<keyword>Ovarian Cancer</keyword>
	<keyword>Breast Cancer</keyword>
	<keyword>Sarcoma</keyword>
	<keyword>Apoptosis</keyword>
	<keyword>MiCK Assay</keyword>
	<keyword>New Technology</keyword>
	<keyword>Patients pathological diagnosis breast , lung , ovarian adenocarcinoma soft tissue sarcoma</keyword>
</DOC>